III-话题@MedSci

#III#

818篇内容 | 2898人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1916566, encodeId=daa719165666f, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=ESMO 2022：双艾组合卡瑞利珠单抗联合阿帕替尼可显著改善不可切除HCC的生存期（SHR-1210-III-310研究）, objectType=article, longId=739071, objectId=dd97e3907119, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd97e3907119, replyNumber=0, likeNumber=119, createdTime=2022-12-30, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd97e3907119, moduleTitle=ESMO 2022：双艾组合卡瑞利珠单抗联合阿帕替尼可显著改善不可切除HCC的生存期（SHR-1210-III-310研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd97e3907119)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916565, encodeId=d2d019165659f, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=NANOBIOTIX与联拓生物宣布，用于评估NBTXR3治疗头颈癌的NANORAY-312 III期试验在亚洲完成首位患者招募, objectType=article, longId=738601, objectId=0e2de3860180, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e2de3860180, replyNumber=0, likeNumber=109, createdTime=2023-08-20, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e2de3860180, moduleTitle=NANOBIOTIX与联拓生物宣布，用于评估NBTXR3治疗头颈癌的NANORAY-312 III期试验在亚洲完成首位患者招募, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e2de3860180)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916557, encodeId=42bd191655e7e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=J Clin Oncol：卡培他滨加用奥沙利铂可作为II-III期结直肠癌的替代辅助治疗, objectType=article, longId=731074, objectId=f8d8e3107483, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8d8e3107483, replyNumber=0, likeNumber=109, createdTime=2023-04-13, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8d8e3107483, moduleTitle=J Clin Oncol：卡培他滨加用奥沙利铂可作为II-III期结直肠癌的替代辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8d8e3107483)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916563, encodeId=948b1916563e4, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=中国之声：首个国产PD-1抑制剂联合双铂化疗新辅助治疗IIB-IIIB期NSCLC安全有效！| WCLC 2022速递, objectType=article, longId=735667, objectId=7b4ee35667af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b4ee35667af, replyNumber=0, likeNumber=158, createdTime=2022-11-30, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b4ee35667af, moduleTitle=中国之声：首个国产PD-1抑制剂联合双铂化疗新辅助治疗IIB-IIIB期NSCLC安全有效！| WCLC 2022速递, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b4ee35667af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916559, encodeId=9bcf191655933, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=一线治疗晚期肝癌哪家强？《柳叶刀肿瘤学》发布卡博替尼+阿替利珠单抗 vs 索拉非尼III期临床结果, objectType=article, longId=731375, objectId=9d30e31375a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d30e31375a9, replyNumber=0, likeNumber=143, createdTime=2023-05-11, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d30e31375a9, moduleTitle=一线治疗晚期肝癌哪家强？《柳叶刀肿瘤学》发布卡博替尼+阿替利珠单抗 vs 索拉非尼III期临床结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d30e31375a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916558, encodeId=32931916558a5, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle= JCO：减量不减效？辅助治疗II/III 期结肠癌，3 个月奥沙利铂+6个月FU并不弱于6个月奥沙利铂+6个月FU！, objectType=article, longId=731245, objectId=ea67e3124570, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea67e3124570, replyNumber=0, likeNumber=121, createdTime=2022-08-14, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea67e3124570, moduleTitle= JCO：减量不减效？辅助治疗II/III 期结肠癌，3 个月奥沙利铂+6个月FU并不弱于6个月奥沙利铂+6个月FU！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea67e3124570)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916544, encodeId=83231916544f2, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=阿斯利康表示Farxiga达到了III期心力衰竭研究的主要终点, objectType=article, longId=726470, objectId=5a4ce2647008, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a4ce2647008, replyNumber=0, likeNumber=111, createdTime=2022-10-15, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a4ce2647008, moduleTitle=阿斯利康表示Farxiga达到了III期心力衰竭研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a4ce2647008)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916548, encodeId=12c019165487a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=A&R：系统性红斑狼疮的共享和亚洲特异性基因座的鉴定以及III型干扰素信号传导和溶酶体功能在该疾病中作用的证据：一项多祖先全基因组关联研究, objectType=article, longId=727241, objectId=7c72e2724187, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c72e2724187, replyNumber=0, likeNumber=166, createdTime=2023-04-14, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c72e2724187, moduleTitle=A&R：系统性红斑狼疮的共享和亚洲特异性基因座的鉴定以及III型干扰素信号传导和溶酶体功能在该疾病中作用的证据：一项多祖先全基因组关联研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c72e2724187)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916549, encodeId=7e3a19165493a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=GEMSTONE-301，舒格利单抗能否再次撼动不可切除III期肺癌治疗格局？, objectType=article, longId=727255, objectId=541de2725547, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=541de2725547, replyNumber=0, likeNumber=94, createdTime=2023-01-28, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=541de2725547, moduleTitle=GEMSTONE-301，舒格利单抗能否再次撼动不可切除III期肺癌治疗格局？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=541de2725547)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916545, encodeId=ec471916545bf, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=绿谷制药GV-971治疗阿尔茨海默病国际多中心III期临床停止, objectType=article, longId=726700, objectId=96ace26700f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96ace26700f7, replyNumber=0, likeNumber=114, createdTime=2022-11-26, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96ace26700f7, moduleTitle=绿谷制药GV-971治疗阿尔茨海默病国际多中心III期临床停止, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96ace26700f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916550, encodeId=bb1119165508b, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=J Clin Oncol：新辅助化疗联合纳武单抗治疗可切除IIIA期非小细胞肺癌的3年预后, objectType=article, longId=727471, objectId=cd20e27471d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd20e27471d6, replyNumber=0, likeNumber=104, createdTime=2022-09-02, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd20e27471d6, moduleTitle=J Clin Oncol：新辅助化疗联合纳武单抗治疗可切除IIIA期非小细胞肺癌的3年预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd20e27471d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916553, encodeId=e98e19165530a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=J Clin Oncol：选择性雌激素受体降解剂（Elacestrant）对比标准内分泌治疗ER+/HR-晚期乳腺癌的疗效：III期临床研究EMERALD, objectType=article, longId=727795, objectId=19a7e27795a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19a7e27795a3, replyNumber=0, likeNumber=94, createdTime=2023-02-18, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19a7e27795a3, moduleTitle=J Clin Oncol：选择性雌激素受体降解剂（Elacestrant）对比标准内分泌治疗ER+/HR-晚期乳腺癌的疗效：III期临床研究EMERALD, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19a7e27795a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916540, encodeId=f63c1916540df, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=BMC Cancer：不可切除III期非小细胞肺癌（NSCLC）铂类放化疗进展后再给予铂类联合化疗可延长生存, objectType=article, longId=723595, objectId=19f4e2359542, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19f4e2359542, replyNumber=0, likeNumber=146, createdTime=2022-10-26, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19f4e2359542, moduleTitle=BMC Cancer：不可切除III期非小细胞肺癌（NSCLC）铂类放化疗进展后再给予铂类联合化疗可延长生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19f4e2359542)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916552, encodeId=26731916552c1, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=JCO：ACHIEVE研究最终结果：III期结肠癌奥沙利铂为基础化疗辅助治疗3个月对比6个月的疗效和安全性, objectType=article, longId=727505, objectId=e820e275056e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e820e275056e, replyNumber=0, likeNumber=111, createdTime=2023-03-31, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e820e275056e, moduleTitle=JCO：ACHIEVE研究最终结果：III期结肠癌奥沙利铂为基础化疗辅助治疗3个月对比6个月的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e820e275056e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916515, encodeId=6642191651549, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=BMC Cancer：阴性淋巴结(NLN)数量对III期结肠癌患者预后影响, objectType=article, longId=295099, objectId=e645295099ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e645295099ce, replyNumber=0, likeNumber=0, createdTime=2022-07-04, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e645295099ce, moduleTitle=BMC Cancer：阴性淋巴结(NLN)数量对III期结肠癌患者预后影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e645295099ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916546, encodeId=27791916546d9, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=Clin Nutrition: 骨骼肌在切除的III期恶性黑色素瘤的患者中具有预后意义, objectType=article, longId=726495, objectId=d831e2649564, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d831e2649564, replyNumber=0, likeNumber=103, createdTime=2022-12-27, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d831e2649564, moduleTitle=Clin Nutrition: 骨骼肌在切除的III期恶性黑色素瘤的患者中具有预后意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d831e2649564)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916564, encodeId=4fb819165648b, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=新型抗凝药asundexian启动 III 期临床研究，评估其在房颤和卒中或短暂性脑缺血高危患者中的疗效, objectType=article, longId=737230, objectId=9f1ae3723033, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f1ae3723033, replyNumber=0, likeNumber=119, createdTime=2023-07-23, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f1ae3723033, moduleTitle=新型抗凝药asundexian启动 III 期临床研究，评估其在房颤和卒中或短暂性脑缺血高危患者中的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f1ae3723033)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916513, encodeId=b37b1916513f5, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=Ther Adv Med Oncol：国内多中心头对头III期研究发现转移性结直肠癌患者二线FOLFIRI方案并不优于单药伊立替康治疗，反而毒性增加, objectType=article, longId=294046, objectId=01c32940469c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01c32940469c, replyNumber=0, likeNumber=89, createdTime=2022-09-22, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01c32940469c, moduleTitle=Ther Adv Med Oncol：国内多中心头对头III期研究发现转移性结直肠癌患者二线FOLFIRI方案并不优于单药伊立替康治疗，反而毒性增加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01c32940469c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916524, encodeId=075f19165248e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=罗氏将启动阿尔茨海默病药物 gantenerumab 的新 III 期研究, objectType=article, longId=299736, objectId=e2b8299e3643, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2b8299e3643, replyNumber=0, likeNumber=142, createdTime=2023-01-16, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2b8299e3643, moduleTitle=罗氏将启动阿尔茨海默病药物 gantenerumab 的新 III 期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2b8299e3643)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916520, encodeId=cd7f19165205d, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=Target Oncol:吴一龙教授IIIb期研究关注近真实世界中afatinib(阿法替尼)治疗EGFR突变阳性NSCLC患者的疗效, objectType=article, longId=295658, objectId=04a8295658c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04a8295658c9, replyNumber=0, likeNumber=125, createdTime=2022-10-14, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04a8295658c9, moduleTitle=Target Oncol:吴一龙教授IIIb期研究关注近真实世界中afatinib(阿法替尼)治疗EGFR突变阳性NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04a8295658c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III

2020-05-29

juliusluan78 (审核中...)

前往app查看评论内容

#III#

ESMO 2022：双艾组合卡瑞利珠单抗联合阿帕替尼可显著改善不可切除HCC的生存期（SHR-1210-III-310研究）

2022-12-30

juliusluan78 (审核中...)

前往app查看评论内容

#III#

NANOBIOTIX与联拓生物宣布，用于评估NBTXR3治疗头颈癌的NANORAY-312 III期试验在亚洲完成首位患者招募

2023-08-20

juliusluan78 (审核中...)

前往app查看评论内容

#III#

J Clin Oncol：卡培他滨加用奥沙利铂可作为II-III期结直肠癌的替代辅助治疗

2023-04-13

juliusluan78 (审核中...)

前往app查看评论内容

#III#

中国之声：首个国产PD-1抑制剂联合双铂化疗新辅助治疗IIB-IIIB期NSCLC安全有效！| WCLC 2022速递

2022-11-30

juliusluan78 (审核中...)

前往app查看评论内容

#III#

一线治疗晚期肝癌哪家强？《柳叶刀肿瘤学》发布卡博替尼+阿替利珠单抗 vs 索拉非尼III期临床结果

2023-05-11

juliusluan78 (审核中...)

前往app查看评论内容

#III#

JCO：减量不减效？辅助治疗II/III 期结肠癌，3 个月奥沙利铂+6个月FU并不弱于6个月奥沙利铂+6个月FU！

2022-08-14

juliusluan78 (审核中...)

前往app查看评论内容

#III#

阿斯利康表示Farxiga达到了III期心力衰竭研究的主要终点

2022-10-15

juliusluan78 (审核中...)

前往app查看评论内容

#III#

A&R：系统性红斑狼疮的共享和亚洲特异性基因座的鉴定以及III型干扰素信号传导和溶酶体功能在该疾病中作用的证据：一项多祖先全基因组关联研究

2023-04-14

juliusluan78 (审核中...)

前往app查看评论内容

#III#

GEMSTONE-301，舒格利单抗能否再次撼动不可切除III期肺癌治疗格局？

2023-01-28

juliusluan78 (审核中...)

前往app查看评论内容

#III#

绿谷制药GV-971治疗阿尔茨海默病国际多中心III期临床停止

2022-11-26

juliusluan78 (审核中...)

前往app查看评论内容

#III#

J Clin Oncol：新辅助化疗联合纳武单抗治疗可切除IIIA期非小细胞肺癌的3年预后

2022-09-02

juliusluan78 (审核中...)

前往app查看评论内容

#III#

J Clin Oncol：选择性雌激素受体降解剂（Elacestrant）对比标准内分泌治疗ER+/HR-晚期乳腺癌的疗效：III期临床研究EMERALD

2023-02-18

juliusluan78 (审核中...)

前往app查看评论内容

#III#

BMC Cancer：不可切除III期非小细胞肺癌（NSCLC）铂类放化疗进展后再给予铂类联合化疗可延长生存

2022-10-26

juliusluan78 (审核中...)

前往app查看评论内容

#III#

JCO：ACHIEVE研究最终结果：III期结肠癌奥沙利铂为基础化疗辅助治疗3个月对比6个月的疗效和安全性

2023-03-31

juliusluan78 (审核中...)

前往app查看评论内容

#III#

BMC Cancer：阴性淋巴结(NLN)数量对III期结肠癌患者预后影响

2022-07-04

juliusluan78 (审核中...)

前往app查看评论内容

#III#

Clin Nutrition: 骨骼肌在切除的III期恶性黑色素瘤的患者中具有预后意义

2022-12-27

juliusluan78 (审核中...)

前往app查看评论内容

#III#

新型抗凝药asundexian启动 III 期临床研究，评估其在房颤和卒中或短暂性脑缺血高危患者中的疗效

2023-07-23

juliusluan78 (审核中...)

前往app查看评论内容

#III#

Ther Adv Med Oncol：国内多中心头对头III期研究发现转移性结直肠癌患者二线FOLFIRI方案并不优于单药伊立替康治疗，反而毒性增加

2022-09-22

juliusluan78 (审核中...)

前往app查看评论内容

#III#

罗氏将启动阿尔茨海默病药物 gantenerumab 的新 III 期研究

2023-01-16

juliusluan78 (审核中...)

前往app查看评论内容

#III#

Target Oncol:吴一龙教授IIIb期研究关注近真实世界中afatinib(阿法替尼)治疗EGFR突变阳性NSCLC患者的疗效

2022-10-14

科室
- - 订阅+
  - 更多科室
工具
服务